Testis cancer: Rare, but curable with promt referral

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 11, 2007, Pages 817-825

  Gilligan, Timothy ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37349077947     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.11.817     Document Type: Review

References (54)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute, 2005.
2. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170:5-11.
3. Powles TB, Bhardwa J, Shamash J, et al. The changing presentation of germ cell tumors of the testis between 1983 and 2002. BJU Int 2005; 95:1197-1200.
4. Ries LAG, Eisner MP, Kosary CL, at al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute, 2003.
5. Theodore C, Terrier-Lacombe MJ, Laplanche A, et al. Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer 2004; 90:55-59.
6. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 US men. J Natl Cancer Inst 2005; 97:1056-1066.
7. Dong C, Lonnstedt I, Hemminki K. Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 2001; 37:1878-1885.
8. Westergaard T, Olsen JH, Frisch M, et al. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. Int J Cancer 1996; 66:627-631.
9. Cortes D, Thorup J, Petersen BL. Testicular neoplasia in unclescencled testes of cryptorchid boys - does surgical strategy have an impact on the risk of invasive testicular neoplasia? Turk J Pediatr 2004; 46(suppl):35-42.
10. Group UKTCS. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. BMJ 1994, 308:1393-1399.
11. Kelsberg G, Bishop R, Morton J, et al. Clinical inquiries. When should a child with an unclescended testis be referred to a urologist? J Fam Pract 2006; 55:336-337.
12. Doria-Rose VP, Biggs ML, Weiss NS. Subfertility and the risk of testicular germ cell tumors (United States). Cancer Causes Control 2005; 16:651-656.
13. Bell D, Morash C, Dranitsaris G, et al. Does prolonging the time to testicular cancer surgery impact long-term cancer control: a systematic review of the literature. Can J Urol 2006, 13(suppi 3):30-36.
14. Calonge N. Screening for testicular cancer: recommendation statement, Am Fam Physician 2005; 72:2069-2070.
15. Daniels IR, Layer GT. Testicular turnours presenting as gynaecomastia. Eur J Surg Oncol 2003; 29:437-439.
16. Steele JP, Oliver RT. Testicular cancer: perils of very late presentation. Lancet 2002; 359:1632-1633.
17. Capelouto CC, Clark PE, Ransil BJ, et al. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995; 153:981-985.
18. Motzer RJ, Bahnson RR, Boston B, et al. National Comprehensive Cancer Network Practice Guidelines in Oncology: Testicular Cancer, Version 1. 2005. Rockledge, PA: National Comprehensive Cancer Network, 2005.
19. Testis. In: Greene FL, Page Di, Fleming ID, et al, editors. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002:347-354.
20. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377-1399.
21. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006; 367:754-765.
22. Chung P, Warde P. Surveillance in stage I testicular seminoma. Urol Oncol 2006, 24:75-79.
23. Oliver RT, Ong J, Shamash J, et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 non-seminoma treated with adjuvant chemotherapy. Urology 2004; 63:556-561.
24. Colls BM, Harvey VJ, Skelton L, et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 1999; 83:76-82.
25. Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol 2004, 22:640-647.
26. Gilligan T, Oh WK, Kantoff PW. Carboplatin for stage I seminoma. J Clin Oncoll 2006, 24:2971-2972; author reply e32-3.
27. Loehrer PJ Sr, Bosl GJ. Carboplatin for stage I seminoma and the sword of Damocles. J Clin Oncol 2005, 23:8566-8569.
28. Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol 2004; 22:225-233.
29. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366:293-300.
30. Aparldo J, Germa JR, del Muro XG, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncoll 2005; 23:8717-8723.
31. Amato RJ, Ro JY, Ayala AG, et al. Risk-adaprted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 2004, 63:144-148, discussion 148-149.
32. Warde P, Gospodarowicz M, Panzarella T, et al. Management of stage II seminoma. J Clin Oncol 1998; 16:290-294.
33. Stephenson AJ, Bosi GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005; 23:2781-2788.
34. Williams S, Birch R, Einhorn L, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engi J Med 1987; 316:1435-1440.
35. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7:387-391.
36. Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13:470-476.
37. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamicle in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16:1287-1293.
38. Saxman SB, Finch D, Gonin R, et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 1998, 16:702-706.
39. Bajorin DF. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11:598-606.
40. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19:1629-1640.
41. de Wit R, Stoter G, Sleljfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78:828-832.
42. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594-603.
43. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamicle, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23:6549-6555.
44. Vuky J, Tickoo SK, Sheinfeld J, et al. Salvage chemotherapy for patients with advanced pure serninoma. J Clin Oncol 2002; 20:297-301.
45. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamicle plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16:2500-2504.
46. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18:3346-3351.
47. Pico Jl,, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16:1152-1159.
48. Flechon A, Bompas E, Biron P, et al. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002; 168:1975-1979.
49. De Santis M, Becherer A. Bokemeyer C, et al. 2-18fluorodeoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchernotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034-1039.
50. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21:1513-1523.
51. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18:1725-1732.
52. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354-1365.
53. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Longterm risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24:467-475.
54. Nuver J, Smit AJ, Wolffenbuttel BHR, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23:3718-3725.